Cargando…
Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma
SIMPLE SUMMARY: The aim of our study was to evaluate whether the CHEK2 mutation was a predictor of poorer clinical course in patients with papillary thyroid cancer. The study included 1547 patients from a single center in Poland, in whom the presence and variant of the CHEK2 mutation were determined...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865996/ https://www.ncbi.nlm.nih.gov/pubmed/33530461 http://dx.doi.org/10.3390/cancers13030470 |
_version_ | 1783647977658646528 |
---|---|
author | Gąsior-Perczak, Danuta Kowalik, Artur Gruszczyński, Krzysztof Walczyk, Agnieszka Siołek, Monika Pałyga, Iwona Trepka, Sławomir Mikina, Estera Trybek, Tomasz Kopczyński, Janusz Suligowska, Agnieszka Ślusarczyk, Rafał Gonet, Agnieszka Jaskulski, Jarosław Orłowski, Paweł Chrapek, Magdalena Góźdź, Stanisław Kowalska, Aldona |
author_facet | Gąsior-Perczak, Danuta Kowalik, Artur Gruszczyński, Krzysztof Walczyk, Agnieszka Siołek, Monika Pałyga, Iwona Trepka, Sławomir Mikina, Estera Trybek, Tomasz Kopczyński, Janusz Suligowska, Agnieszka Ślusarczyk, Rafał Gonet, Agnieszka Jaskulski, Jarosław Orłowski, Paweł Chrapek, Magdalena Góźdź, Stanisław Kowalska, Aldona |
author_sort | Gąsior-Perczak, Danuta |
collection | PubMed |
description | SIMPLE SUMMARY: The aim of our study was to evaluate whether the CHEK2 mutation was a predictor of poorer clinical course in patients with papillary thyroid cancer. The study included 1547 patients from a single center in Poland, in whom the presence and variant of the CHEK2 mutation were determined. Two hundred and forty patients were found to carry this mutation. We found significant association of the CHEK2 truncating variant with vascular invasion and intermediate or high initial risk of recurrence/persistence, whereas this relationship was not found in case of the missense CHEK2 variant. Neither the truncating nor the missense mutations were associated with worse primary treatment response and outcome of the disease. ABSTRACT: The CHEK2 gene is involved in the repair of damaged DNA. CHEK2 germline mutations impair this repair mechanism, causing genomic instability and increasing the risk of various cancers, including papillary thyroid carcinoma (PTC). Here, we asked whether CHEK2 germline mutations predict a worse clinical course for PTC. The study included 1547 unselected PTC patients (1358 women and 189 men) treated at a single center. The relationship between mutation status and clinicopathological characteristics, treatment responses, and disease outcome was assessed. CHEK2 mutations were found in 240 (15.5%) of patients. A CHEK2 I157T missense mutation was found in 12.3%, and CHEK2 truncating mutations (IVS2 + 1G > A, del5395, 1100delC) were found in 2.8%. The truncating mutations were more common in women (p = 0.038), and were associated with vascular invasion (OR, 6.91; p < 0.0001) and intermediate or high initial risk (OR, 1.92; p = 0.0481) in multivariate analysis. No significant differences in these parameters were observed in patients with the I157T missense mutation. In conclusion, the CHEK2 truncating mutations were associated with vascular invasion and with intermediate and high initial risk of recurrence/persistence. Neither the truncating nor the missense mutations were associated with worse primary treatment response and outcome of the disease. |
format | Online Article Text |
id | pubmed-7865996 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-78659962021-02-07 Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma Gąsior-Perczak, Danuta Kowalik, Artur Gruszczyński, Krzysztof Walczyk, Agnieszka Siołek, Monika Pałyga, Iwona Trepka, Sławomir Mikina, Estera Trybek, Tomasz Kopczyński, Janusz Suligowska, Agnieszka Ślusarczyk, Rafał Gonet, Agnieszka Jaskulski, Jarosław Orłowski, Paweł Chrapek, Magdalena Góźdź, Stanisław Kowalska, Aldona Cancers (Basel) Article SIMPLE SUMMARY: The aim of our study was to evaluate whether the CHEK2 mutation was a predictor of poorer clinical course in patients with papillary thyroid cancer. The study included 1547 patients from a single center in Poland, in whom the presence and variant of the CHEK2 mutation were determined. Two hundred and forty patients were found to carry this mutation. We found significant association of the CHEK2 truncating variant with vascular invasion and intermediate or high initial risk of recurrence/persistence, whereas this relationship was not found in case of the missense CHEK2 variant. Neither the truncating nor the missense mutations were associated with worse primary treatment response and outcome of the disease. ABSTRACT: The CHEK2 gene is involved in the repair of damaged DNA. CHEK2 germline mutations impair this repair mechanism, causing genomic instability and increasing the risk of various cancers, including papillary thyroid carcinoma (PTC). Here, we asked whether CHEK2 germline mutations predict a worse clinical course for PTC. The study included 1547 unselected PTC patients (1358 women and 189 men) treated at a single center. The relationship between mutation status and clinicopathological characteristics, treatment responses, and disease outcome was assessed. CHEK2 mutations were found in 240 (15.5%) of patients. A CHEK2 I157T missense mutation was found in 12.3%, and CHEK2 truncating mutations (IVS2 + 1G > A, del5395, 1100delC) were found in 2.8%. The truncating mutations were more common in women (p = 0.038), and were associated with vascular invasion (OR, 6.91; p < 0.0001) and intermediate or high initial risk (OR, 1.92; p = 0.0481) in multivariate analysis. No significant differences in these parameters were observed in patients with the I157T missense mutation. In conclusion, the CHEK2 truncating mutations were associated with vascular invasion and with intermediate and high initial risk of recurrence/persistence. Neither the truncating nor the missense mutations were associated with worse primary treatment response and outcome of the disease. MDPI 2021-01-26 /pmc/articles/PMC7865996/ /pubmed/33530461 http://dx.doi.org/10.3390/cancers13030470 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Gąsior-Perczak, Danuta Kowalik, Artur Gruszczyński, Krzysztof Walczyk, Agnieszka Siołek, Monika Pałyga, Iwona Trepka, Sławomir Mikina, Estera Trybek, Tomasz Kopczyński, Janusz Suligowska, Agnieszka Ślusarczyk, Rafał Gonet, Agnieszka Jaskulski, Jarosław Orłowski, Paweł Chrapek, Magdalena Góźdź, Stanisław Kowalska, Aldona Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title | Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title_full | Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title_fullStr | Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title_full_unstemmed | Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title_short | Incidence of the CHEK2 Germline Mutation and Its Impact on Clinicopathological Features, Treatment Responses, and Disease Course in Patients with Papillary Thyroid Carcinoma |
title_sort | incidence of the chek2 germline mutation and its impact on clinicopathological features, treatment responses, and disease course in patients with papillary thyroid carcinoma |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865996/ https://www.ncbi.nlm.nih.gov/pubmed/33530461 http://dx.doi.org/10.3390/cancers13030470 |
work_keys_str_mv | AT gasiorperczakdanuta incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT kowalikartur incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT gruszczynskikrzysztof incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT walczykagnieszka incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT siołekmonika incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT pałygaiwona incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT trepkasławomir incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT mikinaestera incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT trybektomasz incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT kopczynskijanusz incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT suligowskaagnieszka incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT slusarczykrafał incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT gonetagnieszka incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT jaskulskijarosław incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT orłowskipaweł incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT chrapekmagdalena incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT gozdzstanisław incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma AT kowalskaaldona incidenceofthechek2germlinemutationanditsimpactonclinicopathologicalfeaturestreatmentresponsesanddiseasecourseinpatientswithpapillarythyroidcarcinoma |